Trial Profile
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide Followed by Rituximab/Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-Finding Study With Concomitant Evaluation of Safety and Efficacy.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms RevliRit
- 01 Oct 2018 Results published in the Annals of Hematology
- 26 May 2012 Company added to the associations field as reported by European Clinical Trials Database record.
- 09 May 2011 Planned end date changed from 1 Mar 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.